Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer

Conditions: Metastatic Cancer

Interventions: Other: molecular profiling, patient derived cells

First Posted Date: 2016-01-05

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 500

Registration Number: NCT02646228

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Korea, Republic of

Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy

Not Applicable

Recruiting

Conditions: Pediatric Cancer Patients

Interventions: Radiation: Proton therapy

First Posted Date: 2016-01-01

Last Posted Date: 2016-10-14

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 400

Registration Number: NCT02644993

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Phase 2

Conditions: Relapsed Pediatric Solid Tumor
Refractory Pediatric Solid Tumor
Relapsed Pediatric AML
Refractory Pediatric AML

Interventions: Procedure: CancerSCAN™
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Fludarabine
Drug: Cytarabine
Drug: Pazopanib
Drug: Sorafenib
Drug: Axitinib
Drug: Crizotinib
Drug: Dasatinib
Drug: Erlotinib
Drug: Everolimus
Drug: Imatinib
Drug: Ruxolitinib
Drug: Vandetanib
Drug: Vemurafenib
Drug: Trastuzumab

First Posted Date: 2015-12-23

Last Posted Date: 2020-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 90

Registration Number: NCT02638428

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome

Conditions: Irritable Bowel Syndrome

First Posted Date: 2015-12-23

Last Posted Date: 2015-12-24

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 118

Registration Number: NCT02638870

Locations: 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial

Phase 2

Conditions: Liver Neoplasm
Proton Therapy

Interventions: Radiation: Proton arm

First Posted Date: 2015-12-17

Last Posted Date: 2018-04-12

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT02632864

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Phase 1

Completed

Conditions: Refractory Cancer

Interventions: Drug: AZD6738
Drug: Paclitaxel

First Posted Date: 2015-12-15

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 65

Registration Number: NCT02630199

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Korea, Republic of

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2015-12-11

Last Posted Date: 2020-11-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 62

Registration Number: NCT02628951

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor

Phase 2

Completed

Conditions: Thymic Epithelial Tumors

Interventions: Drug: Pembrolizumab

First Posted Date: 2015-11-18

Last Posted Date: 2020-07-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 33

Registration Number: NCT02607631

EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors

Not Applicable

Completed

Conditions: Alopecia

Interventions: Other: Placebo
Other: CG428

First Posted Date: 2015-11-16

Last Posted Date: 2018-09-04

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 32

Registration Number: NCT02605629

Locations: 🇰🇷
Danbee Kang, Seoul, Korea, Republic of

REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)

Conditions: Acute Coronary Syndromes

Interventions: Device: Bioresorbable scaffold (BRS)

First Posted Date: 2015-11-10

Last Posted Date: 2017-03-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 1000

Registration Number: NCT02601404

Locations: 🇰🇷
Cardiac and Vascular Center; Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy